Ophthalmic treatment systems and methods of using the systems are disclosed. The ophthalmic treatment systems include (a) a light source device; (b) at least one optical treatment head operatively coupled to the light source device, comprising a light source array, and providing at least one treatment light; and (c) a light control device, which (i) provides patterned or discontinuous treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye); or (ii) adjusts intensity of part or all of the light source array, providing adjusted intensity treatment light projection onto an eye (e.g., the cornea and/or sclera of an eye). The at least one treatment light promotes corneal and/or scleral collagen cross-linking.

An elongate electrode is configured to flex and generate plasma to incise tissue. An electrical energy source operatively coupled to the electrode is configured to provide electrical energy to the electrode to generate the plasma. A tensioning element is operatively coupled to the elongate electrode. The tensioning element can be configured to provide tension to the elongate electrode to allow the elongate electrode to flex in response to the elongate electrode engaging the tissue and generating the plasma. The tensioning element operatively coupled to the flexible elongate electrode may allow for the use of a small diameter electrode, such as a 5 m to 20 m diameter electrode, which can allow narrow incisions to be formed with decreased tissue damage. In some embodiments, the tensioning of the electrode allows the electrode to more accurately incise tissue by decreasing variations in the position of the electrode along the incision path.

The present disclosure provides an intralocular-lens (IOL) or ophthalmic device including an optic and at least one haptic, at least a portion of which is formed from a photoresponsive shape memory polymer network, such as a polydomain azo liquid crystalline polymer network (PD-LCN). The present disclosure further provides systems and methods for adjusting the position of such an IOL or other ophthalmic device using polarized laser radiation.

An example system for tracking motion of an eye during an eye treatment includes an image capture device configured to capture a plurality of images of an eye. The system includes an ensemble tracker employing a first, second, and third tracker to process a plurality of images. Each tracker is configured to detect a respective feature in the plurality of images and provide, based on the respective feature, a respective set of data relating to motion of the eye. The first tracker detects a first feature including an anatomical structure in an iris region of the eye. The second tracker detects a second feature including a shape defined by a contrast between the iris region and a pupil region. A third tracker detects a third feature including a boundary between the iris region and the pupil region of the eye.

An example system for corneal treatment includes an illumination system to generate cross-linking in at least one selected region of a cornea treated with a cross-linking agent by delivering photoactivating light according to photoactivation parameters. The system includes a controller to receive input relating to treatment parameters, which include the photoactivation parameters. The controller is configured to output information for adjusting the one or more treatment parameters by (A) determining from the input, a distribution of cross-links for at least one selected region of the cornea; and (B) determining, from the distribution of cross-links, a shape change for the cornea. Responsive to the output from the controller, the illumination system is configured to adjust at least one of the one or more photoactivation parameters and determine a shape change according to a biomechanical model, and at least one of a biochemical model or an optical mode.

A system and method for corneal cross-linking with real-time monitoring are provided. The method comprises determining a plurality of measurement locations in a region of a cornea, and applying a corneal cross-linking treatment to the region of the cornea. During the application of the corneal cross-linking treatment, the method also comprises acquiring a temporal OCT interferogram at each OCT measurement location, generating temporal complex OCT data based on the temporal OCT interferogram, determining biomechanical data based on the temporal complex OCT data, and adjusting the corneal cross-linking treatment based on the biomechanical data.

The present invention relates to a device for permanently changing the color of the iris, such as from brown to blue. The invention is a system that includes a slit lamp microscope, a source of intense pulsed light (IPL), optical tracking and measuring systems, and a device that prevents the application of light to the pupil. The IPL provides a simultaneous application of a range of wavelengths, rather than the single wavelength typically applied by lasers. In a preferred embodiment, the IPL is applied as annular ring, striking only the iris and not the pupil or the sclera. Air or liquid cooling can be used to prevent the eye from overheating.

Wounds in the eye following surgery or injury are sealed by soaking the area with a riboflavin solution containing iodide ion and irradiating the wound area with UVA radiation in a selected wavelength range for a selected time period to promote cross-linking of tissue between opposite surfaces of the wound or between the incised wound surfaces and a graft or implant.

A formulation for an eye treatment includes a photosensitizer and a permeability enhancing composition. The permeability enhancing composition includes one or more permeability enhancers. The permeability enhancing composition has a hydrophilic and lipophilic balance increases a permeability of an area of the eye for the photosensitizer. The hydrophilic and lipophilic balance can be characterized by a Hydrophile-Lipophile Balance (HLB) number. For example, the area of the eye may include a corneal epithelium, the photosensitizer may include riboflavin, and the permeability enhancing composition may have a corresponding HLB number between approximately 12.6 and approximately 14.6.

The invention provides a method of noninvasively treating a condition associated with reduced integrity or increased permeability of an epithelial layer by a series of magnetic pulses having a magnitude of up to 3 T, wherein the magnetic pulses are designed to induce an electric field having a magnitude of up to 250 Volt per meter adjacent to a target treatment area, the condition particularly being ocular condition associated with reduced barrier function of the cornea. The invention provides a device for effecting the tissue treatment, creating series of pulses exhibiting a rate of change of more than 200 T/s in the absolute value.